Search Results
Search for other papers by P E L√∏nning in
Google Scholar
PubMed
Search for other papers by T S√∏rlie in
Google Scholar
PubMed
Search for other papers by C M Perou in
Google Scholar
PubMed
Search for other papers by P O Brown in
Google Scholar
PubMed
Search for other papers by D Botstein in
Google Scholar
PubMed
Search for other papers by A L B√∏rresen-Dale in
Google Scholar
PubMed
Current development in molecular techniques has extended the opportunities to explore genetic alterations in malignant tissue. There is a need to improve prognostication and, in particular, to understand the mechanisms of treatment resistance in different tumours. Gene analyses by microarrays allow concomitant analyses of several genes in concert, providing new opportunities for tumour classification and understanding of key biological disturbances. This paper outlines our continuing studies exploring prognostic and, we hope, predictive factors in breast cancer therapy.
Search for other papers by Rossella Libè in
Google Scholar
PubMed
Search for other papers by Amato Fratticci in
Google Scholar
PubMed
Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed
monoclonal populations of cells, whereas benign tumors might be monoclonal as well as polyclonal ( Beuschlein et al. 1994 , Gicquel et al. 1994 ). Monoclonal tumors result from genetic alterations conferring a growth advantage to the cell
Search for other papers by S F Brewster in
Google Scholar
PubMed
Search for other papers by X Yang in
Google Scholar
PubMed
Search for other papers by L Yan in
Google Scholar
PubMed
Search for other papers by N E Davidson in
Google Scholar
PubMed
Like all cancers, breast cancer is considered to result in part from the accumulation of multiple genetic alterations leading to oncogene overexpression and tumor suppressor loss. More recently, the role of epigenetic change as a distinct and crucial mechanism to silence a variety of methylated tissue-specific and imprinted genes has emerged in many cancer types. This review will briefly discuss basic aspects of DNA methylation, recent advances in DNA methyltransferases, the role of altered chromatin organization and the concept of gene transcriptional regulation built on methylated CpGs. In particular, we discuss epigenetic regulation of certain critical tumor suppressor and growth regulatory genes implicated in breast cancer, and its relevance to breast cancer diagnosis, prognosis, progression and therapy.
Graduate Program in Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, Minnesota, USA
Search for other papers by Mark Daniel in
Google Scholar
PubMed
Search for other papers by Todd P Knutson in
Google Scholar
PubMed
Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
Search for other papers by Jamie M Sperger in
Google Scholar
PubMed
Search for other papers by Yingming Li in
Google Scholar
PubMed
Search for other papers by Anupama Singh in
Google Scholar
PubMed
Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
Search for other papers by Charlotte N Stahlfeld in
Google Scholar
PubMed
Search for other papers by Courtney Passow in
Google Scholar
PubMed
Search for other papers by Benjamin Auch in
Google Scholar
PubMed
Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
Search for other papers by Joshua M Lang in
Google Scholar
PubMed
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA
Department of Urology, University of Minnesota, Minneapolis, Minnesota, USA
Search for other papers by Scott M Dehm in
Google Scholar
PubMed
Castration-resistant prostate cancer (CRPC) is driven by AR gene aberrations that arise during androgen receptor (AR)-targeted therapy. AR amplification and mutations have been profiled in circulating tumor cells (CTCs), but whether AR gene rearrangements can be assessed in CTCs is unknown. In this study, we leveraged CRPC cell lines with defined AR gene rearrangements to develop and validate a CTC DNA analysis approach that utilized whole genome amplification and targeted DNA-sequencing of AR and other genes important in CRPC. We tested the utility of this approach by analyzing matched CTC DNA and plasma cell-free DNA (cfDNA) from a case series of ten CRPC patients. One of ten CTC samples and two of ten cfDNA samples were positive for AR gene rearrangements. All AR gene rearrangements were discordant between matched liquid biopsy samples. One patient harbored separate AR gene rearrangements in CTC DNA and cfDNA, but concordant AR amplification and AR T878A mutation. This patient also displayed concordant loss of TP53 and PTEN, but the loss of RB1 in cfDNA only. The overall frequency of discordant alterations in these genes between matched CTC DNA and cfDNA was high. This study establishes the technical feasibility of analyzing structural rearrangements, mutations, and copy number variants in AR and other CRPC genes using two different sources of DNA from a single blood sample. Paired CTC DNA and cfDNA analysis may have utility for capturing the heterogeneity of genetic alterations in CRPC patients.
Search for other papers by Asterios Karagiannis in
Google Scholar
PubMed
Search for other papers by Dimitri P Mikhailidis in
Google Scholar
PubMed
Search for other papers by Vasilios G Athyros in
Google Scholar
PubMed
Search for other papers by Faidon Harsoulis in
Google Scholar
PubMed
Pheochromocytomas (PHEOs) are rare neoplasms that produce catecholamines and usually arise from the adrenal medulla and are considered to be an adrenal paraganglioma (PGL). Closely related tumors of extraadrenal sympathetic and parasympathetic paraganglia are classified as extraadrenal PGLs. Most PHEOs are sporadic, but a significant percentage (∼25%) may be found in patients with germline mutations of genes predisposing to the development of von Hippel–Lindau disease, neurofibromatosis 1, multiple endocrine neoplasia type 1 (MEN1) and 2 (MEN2), and the PGL/PHEOs syndrome, based on the described mutations of the genes for succinate dehydrogenase subunit D (SDHD), B (SDHB), and C (SDHC). As one out of four PHEOs turns out to be a hereditary clinical entity, screening for genetic alterations is important, as it provides useful information for a rational diagnostic approach and management. This review discusses the genetics, the pathophysiology of hypertension, the clinical picture, the biochemical and imaging diagnosis, and the preferred therapeutic approach for PGLs/PHEOs. Furthermore, it emphasizes the need for genetic testing in cases with apparently sporadic PHEOs.
Université Paris-Sud Orsay, Île-de-France, France
Gustave Roussy, Villejuif, France
Search for other papers by Monia Zidane in
Google Scholar
PubMed
Search for other papers by Jean-Baptiste Cazier in
Google Scholar
PubMed
Search for other papers by Sylvie Chevillard in
Google Scholar
PubMed
Search for other papers by Catherine Ory in
Google Scholar
PubMed
Gustave Roussy, Villejuif, France
UMR 8200 CNRS, Villejuif, France
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Gustave Roussy, Villejuif, France
UMR 8200 CNRS, Villejuif, France
Search for other papers by Corinne Dupuy in
Google Scholar
PubMed
Search for other papers by Jean-François Deleuze in
Google Scholar
PubMed
Search for other papers by Anne Boland in
Google Scholar
PubMed
Université Paris-Sud Orsay, Île-de-France, France
Gustave Roussy, Villejuif, France
Search for other papers by Nadia Haddy in
Google Scholar
PubMed
PSL Research University, Paris, France
INSERM, U900, Paris, France
Mines Paris Tech, Fontainebleau, France
Search for other papers by Fabienne Lesueur in
Google Scholar
PubMed
Université Paris-Sud Orsay, Île-de-France, France
Gustave Roussy, Villejuif, France
Search for other papers by Florent de Vathaire in
Google Scholar
PubMed
The first study establishing exposure to ionizing radiations (IRs) as a risk factor for differentiated thyroid cancer (DTC) was published 70 years ago. Given that radiation exposure causes direct DNA damage, genetic alterations in the different DNA repair mechanisms are assumed to play an important role in long-term IR-induced DNA damage prevention. Individual variations in DNA repair capacity may cause different reactions to damage made by IR exposure. The aim of this review is to recapitulate current knowledge about constitutional genetic polymorphisms found to be significantly associated with DTC occurring after IR exposure. Studies were screened online using electronic databases – only fully available articles, and studies performed among irradiated population or taking radiation exposure as adjustment factors and showing significant results are included. Nine articles were identified. Ten variants in/near to genes in six biological pathways, namely thyroid activity regulations, generic transcription, RET signaling, ATM signaling and DNA repair pathways were found to be associated with radiation-related DTC in these studies. Only seven variants were found to be in interaction with IR exposure in DTC risk. Most of these variants are also associated to sporadic DTC and are not specific to IR-related DTC. In the published studies, no data on children treated with radiotherapy is described. In conclusion, more studies carried out on larger cohorts or on case–control studies with well-documented individual radiation dose estimations are needed to get a comprehensive picture of genetic susceptibility factors involved in radiation-related DTC.
Search for other papers by D Führer in
Google Scholar
PubMed
Search for other papers by A Tannapfel in
Google Scholar
PubMed
Search for other papers by O Sabri in
Google Scholar
PubMed
Search for other papers by P Lamesch in
Google Scholar
PubMed
Search for other papers by R Paschke in
Google Scholar
PubMed
In a 59-year-old patient, thyroid follicular cancer was diagnosed in two right-sided toxic thyroid nodules, which had presented clinically as unilateral thyroid autonomy. In addition, the patient had histologically proven lung metastases of thyroid cancer; however, these failed to exhibit iodine uptake and were resistant to radioiodine treatment. The functional activity of the thyroid nodules prompted us to screen for TSH receptor (TSHR) mutations, and the histological diagnosis of follicular carcinoma led us to search for the PAX8-PPARgamma1 rearrangement and mutations in the ras genes. Each thyroid nodule harboured a different TSHR mutation (large nodule, Asp633Tyr; small nodule, Phe631Ile). Presence of both mutations in one sample suggestive of local invasion of a thyroid carcinoma could not be demonstrated, although several specimens from different nodule locations were screened. Only the wild-type TSHR sequence was identified in the histologically normal left thyroid lobe, and no genetic alterations were found in the other investigated genes. No TSHR mutations were detected in the pulmonary metastases. This is the first case report of a patient with toxic follicular thyroid carcinoma harbouring two different TSHR mutations and presenting with non-functional lung metastases.
Search for other papers by P Roy-Burman in
Google Scholar
PubMed
Search for other papers by H Wu in
Google Scholar
PubMed
Search for other papers by W C Powell in
Google Scholar
PubMed
Search for other papers by J Hagenkord in
Google Scholar
PubMed
Search for other papers by M B Cohen in
Google Scholar
PubMed
This review is focused on mouse models for prostate cancer that have been designed on the basis of genetic alterations that are frequently found in human prostate cancer. It begins with an analysis of the similarities and differences in the gross and microscopic anatomy of the mouse and human prostate glands, and extends to the pathologies induced in the genetically manipulated mouse prostate in comparison with the sporadic development of the disease in humans. Major achievements have been made in modeling human prostate cancer in mice in recent years. There are models which display slow, temporal development of increasingly severe preneoplastic lesions, which are remarkably restricted to the prostate gland, a property similar to the aging-related progression of these lesions in humans. Other models rapidly progress to local invasive adenocarcinoma, and, in some of them metastasis is manifested subsequently with defined kinetics. Global assessment of molecular changes in the prostate of the genetically manipulated mice is increasingly underscoring the validity of the models through identification of 'signature' genes which are associated with the organ-confined primary or distant metastases of human prostate cancer. Taken together, various 'natural' models depicting stages of the disease, ranging from the early preneoplastic lesions to metastatic prostate cancer, now provide new tools both for exploring the molecular mechanism underlying prostate cancer and for development or testing of new targeted therapies.
Departments of Orthopaedic Surgery, Physiology and Biophysics, Radiation Oncology, Breast Cancer Research Program, Hematology and Oncology, Barton Research Institute, Center for Orthopaedic Research
Departments of Orthopaedic Surgery, Physiology and Biophysics, Radiation Oncology, Breast Cancer Research Program, Hematology and Oncology, Barton Research Institute, Center for Orthopaedic Research
Search for other papers by Larry J Suva in
Google Scholar
PubMed
Departments of Orthopaedic Surgery, Physiology and Biophysics, Radiation Oncology, Breast Cancer Research Program, Hematology and Oncology, Barton Research Institute, Center for Orthopaedic Research
Search for other papers by Robert J Griffin in
Google Scholar
PubMed
Departments of Orthopaedic Surgery, Physiology and Biophysics, Radiation Oncology, Breast Cancer Research Program, Hematology and Oncology, Barton Research Institute, Center for Orthopaedic Research
Search for other papers by Issam Makhoul in
Google Scholar
PubMed
Cancer development is a multi-step process driven by genetic alterations that elicit the progressive transformation of normal human cells into highly malignant derivatives. The altered cell proliferation phenotype of cancer involves a poorly characterized sequence of molecular events, which often result in the development of distant metastasis. In the case of breast cancer, the skeleton is among the most common of metastatic sites. In spite of its clinical importance, the underlying cellular and molecular mechanisms driving bone metastasis remain elusive. Despite advances in our understanding of the phenotype of cancer cells, the increased focus on the contribution of the tumor microenvironment and the recent revival of interest in the role of tumor-propagating cells (so called cancer stem cells) that may originate or be related to normal stem cells produced in the bone marrow, many important questions remain unanswered. As such, a more complete understanding of the influences of both the microenvironment and the tumor phenotype, which impact the entire multi-step metastatic cascade, is required. In this review, the importance of tumor heterogeneity, tumor-propagating cells, the microenvironment of breast cancer metastasis to bone as well as many current endocrine therapies for the prevention and treatment of metastatic breast cancer is discussed.
